Skip to main content

Follow us

Home

Search

the Gateway to Research in Oklahoma

  • Researchers
  • Providers
  • Patients
  • About GRO

Gateway to Research in Oklahoma


Oklahoma Shared Clinical and Translational Resources U54 GM104938

Researchers

imgResearchers

The GRO: Researcher Portal provides resources, information, and training to help individuals or communities involved in performing clinical and translational research in Oklahoma.

Providers

imgProviders

The GRO: Provider Portal assists medical providers to identify clinical research opportunities in Oklahoma, tools for patient education, and evidence-based resources to improve patient care.

Patients

imgPatients

The GRO: Patient Portal can help patients and families to learn more about clinical and translational research and to connect with opportunities to participate in research opportunities in your communities.

Oklahoma Research Highlights

StoichLife: A Global Dataset of Plant and Animal Elemental Content

2 months 3 weeks ago
The elemental content of life is a key trait shaping ecology and evolution, yet organismal stoichiometry has largely been studied on a case-by-case basis. This limitation has hindered our ability to identify broad patterns and mechanisms across taxa and ecosystems. To address this, we present StoichLife, a global dataset of 28,049 records from 5,876 species spanning terrestrial, freshwater, and marine realms. Compiled from published and unpublished sources, StoichLife documents elemental content...
Angélica L González

Worsening Renal Function Is Common and Associated With Higher Mortality in Cardiogenic Shock: A Cardiogenic Shock Working Group Report

2 months 3 weeks ago
CONCLUSION: WRF is common and deleterious in both HF- and AMI-CS. Given the early association with worse outcomes, WRF may not only be prognostic but also represent a potential therapeutic target in future CS studies.
Rachna Kataria

EUROPA trial: cost implications of radiotherapy versus endocrine therapy

2 months 3 weeks ago
No abstract
Shearwood McClelland

Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial

2 months 3 weeks ago
BACKGROUND: Mirvetuximab soravtansine-gynx (MIRV) is a first-in-class antibody-drug conjugate targeting folate receptor α (FRα), approved by the US Food and Drug Administration for the treatment of platinum-resistant ovarian cancer in the USA. Here, we report patient-reported outcomes for participants treated with MIRV compared with investigator's choice of chemotherapy from the phase 3 MIRASOL trial, which met its primary endpoint of progression-free survival and key secondary endpoints of...
Toon Van Gorp

Short- and long-term effects of uterine disease on oocyte developmental capacity in postpartum dairy cows

2 months 3 weeks ago
The hypothesis was that early postpartum uterine disease would reduce the developmental capacity of oocytes thus contributing to the reduced fertility of dairy cows with uterine disease. Dairy cows were diagnosed healthy or with metritis at 7-10 d postpartum. The reproductive tract was collected at approximately 1 mo (Exp. 1) or approximately 80 or 165 d (Exp. 2) postpartum for the collection of cumulus-oocyte complexes (COC). The COC were matured, co-incubated with sperm for fertilization, and...
M O Caldeira

Pagination

  • Previous page ‹ Previous
  • Page 45
  • Next page Next ›
Subscribe to

octsi logo

1000 N. Lincoln Blvd, Suite 2100, Oklahoma City, OK 73104
Copyright © 2021 The Board of Regents of the University of Oklahoma, All Rights Reserved.

About GRO

News
Publications
FAQ

Terms of Use

Privacy Policy
Accessibility

Contact

info email
info phone
Copyright © 2025. All rights reserved. Designed By Zymphonies